Trastuzumab
An antineoplastic drug, it is given in combination with paclitaxel or docetaxel, for metastatic breast cancer and in whom anthracycline treatment is inappropriate. It may be given as a monotherapy. It is given by IV-infusion.
Primary Characteristics
It is of Natural origin.
Non-proprietary name: Trastuzumab.
Pharmacokinetics
None recorded.
Advertisement
Indications
Trastuzumab is primarily indicated in conditions like Metastatic breast cancer, Metastatic carcinoma of breast.
Contraindications
Trastuzumab is contraindicated in conditions like Breast feeding, Severe dyspnea at rest.
Dosage
Trastuzumab's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 4 mg/kg | 4 mg/kg | — | IV-Inf (over 90 min) | Initially; followed by 2 mg/kg over 30 min at weekly intervals. |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Trastuzumab in overdosage may give rise to further complications which include Cardiovascular toxicity , Ventricular dysfunction, Congestive heart failure , Thromboembolic stroke.
Trastuzumab is known to cause more or less tolerable side effects which are usually transient. These include Anemia, Anorexia , Chills, Cough , Diarrhea, Dizziness, Dyspnea, Edema, Fever, Headache, Infection, Inflammation, Infusion reactions, 1st dose, Insomnia, Leukopenia, Nausea and vomiting, Pain , Paresthesias, Rashes .
Warnings / Precautions
Available Brands
None recorded.
Drug Classification
- 1.8.2 — Cytotoxic (anti-neoplastic) drugs